Publications by authors named "Connie Keyserling"
Effect of Serial Infusions of CER-001, a Pre-β High-Density Lipoprotein Mimetic, on Coronary Atherosclerosis in Patients Following Acute Coronary Syndromes in the CER-001 Atherosclerosis Regression Acute Coronary Syndrome Trial: A Randomized Clinical Trial.
Stephen J Nicholls
,
Jordan Andrews
,
John J P Kastelein
,
Bela Merkely
,
Steven E Nissen
,
Connie Keyserling
JAMA Cardiol
September 2018
Article Synopsis
- CER-001 is an engineered HDL mimetic showing promise in reducing cholesterol and vascular inflammation, with a previous study indicating potential plaque regression in patients with high coronary plaque burden.
- The objective of the latest study was to assess the effect of CER-001 infusions on coronary atherosclerosis progression in patients already on statins.
- Conducted as a double-blind trial, 272 participants received either CER-001 or placebo over 10 weeks, focusing on changes in atheroma volume and overall safety.
Article Synopsis
- High-density lipoprotein (HDL) has protective properties against heart disease, but effective treatments based on HDL are still under research; the CARAT trial aims to test a new HDL mimetic called CER-001 on patients following acute coronary syndrome (ACS).
- In this phase 2 trial, 292 patients with significant atheroma volume will receive either CER-001 or a placebo through ten infusions over ten weeks, with assessments of their coronary artery condition before and after treatment.
- The primary goal is to measure changes in atheroma volume and evaluate the safety and tolerability of CER-001, potentially offering a new way to treat atherosclerosis in at-risk patients.